BioSpace News Archive

Lively, Inc., creators of the modern Health Savings Account (HSA), today released its second annual HSA Spend Report, giving a view into how and where consumers spend on healthcare costs each year

Freenome, a privately-held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection through a routine blood draw, is presenting data from their prospective, multi-center clinical study AI-EMERGE®

Two, four-person teams bested the competition at the National Finals of the National Kidney Foundation Konica Minolta Golf Classic, held January 16-19 at the legendary Pebble Beach Resorts in California.

Centinel Spine®, LLC, the largest privately-held spine company focused on anterior column reconstruction, today announced that its current partnership with Performance Tech Motorsports as Title Sponsor for the team will continue through the 2020 IMSA WeatherTech SportsCar Championship season after successful programs the past several years.

PrimaryPlus (https://primaryplus.net) and PursueCare (https://www.pursuecare.com) today announced that they have partnered to launch an integrated telehealth addiction and behavioral health treatment model serving rural populations across PrimaryPlus’ Kentucky footprint which includes seven health center locations.

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, an independent provider of global commercial services to the life science industry, today announced a collaboration to utilize EVERSANA’s integrated suite of outsourced services to commercialize and distribute Gimoti™ in the United States (U.S.).

BlackThorn Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing targeted medicines to treat central nervous system (CNS) disorders, today announced the advancement of Phase 2 clinical development for its lead drug candidate, BTRX-335140 (BTRX-140), a selective antagonist for the kappa opioid receptor (KOR)

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Garry Nicholson to its board of directors.

Today, UNICEF USA’s Board of Directors announced that Michael J. Nyenhuis has been selected as the organization’s new president and CEO.